The Safety Signal: Building a Just Culture in Allergy and Immunology

Innate lymphoid cells or ILCs respond rapidly to help defend mucosal barriers, maintain tissue homeostasis and shape the adaptive immune response that follows. In this episode, Taylor A. Doherty, MD, FAAAAI, will discuss the importance of ILCs and what we know about these uniquely positioned cells in allergic disease.

Eosinophilia has a broad differential and determining how to most effectively evaluate it can be challenging. In this episode, we’ll work through a clinical case with Paneez Khoury, MD, MHSc, FAAAAI, and discuss how understanding eosinophil biology can guide our evaluation and management.

Gene editing has moved from the laboratory to the clinic and is likely to transform treatment for our patients with inborn errors of immunity. In this episode, Caroline Kuo, MD, explains genome editing technologies and how these tools may enable precise, potentially curative therapies. 

The LEAP trial fundamentally changed our understanding of immune tolerance, demonstrating that early oral exposure can dramatically reduce the risk of developing peanut allergy. In this episode, Edwin Kim, MD, FAAAAI, will help us explore the immunologic mechanisms of early food introduction and tolerance development and what the evidence tells us about other food allergies.

Join us as Kelly Stone, MD, PhD, FAAAAI, explains the evolution of the U.S. Food and Drug Administration and its central role in ensuring the safety and efficacy of therapeutics in the United States. We discuss the modern drug approval process from preclinical development through clinical trials and post-marketing surveillance  and explore what makes this pathway different for biologics and biosimilars so you have a better understanding of the therapeutics that we prescribe every day in the clinic.BiosimilarsMedWatch:The FDA Safety Information and Adverse Event Reporting Program FDA HistoryDrug Development Process

Join us as Derek Chu, MD, PhD, explores the paradigm shift in treating atopic dermatitis as a systemic, immune-driven disease rather than a localized skin condition. We discuss the updates to the practice parameters including practical guidance on integrating of novel topicals, biologics, and JAK inhibitors into our treatment as well as the upcoming practice parameters on chronic spontaneous urticaria. Continuing Medical Education credit is available with this episode. Complete the assessment and claim credit. .75 AMA PRA Category 1 Credit(s)™ 

Join us as Monica Kraft, MD, FAAAAI, provides an evidence-based framework for managing allergic conditions during pregnancy, focusing on the safety of commonly used medications, from inhaled corticosteroids and antihistamines to biologics. We address the risks of undertreated asthma and explore the latest recommendations for penicillin allergy delabeling to optimize maternal-fetal outcomes. The discussion offers practical strategies for collaborating with OB-GYN colleagues to ensure safe, effective treatment throughout every trimester.View the Work Group Report: Penicillin Allergy Delabeling Can and Should Be Performed in Pregnant Patients: A Work Group Report of the AAAAI Women’s Health in Allergy and Immunology and Adverse Reaction to Drugs, Biologics and Vaccines Committees

In this episode, Christine Cho, MD, FAAAAI, discusses analyzing medical errors within the allergy clinic, from incorrect immunotherapy dosing to the systemic risks of penicillin mislabeling. Dr. Cho explains how shifting from a culture of blame to a "just culture" allows practices to transform "near misses" into learning opportunities that create more robust, reliable systems.

In honor of Food Allergy Awareness Week, we’re stepping out of the clinic and into the heat of the kitchen. Chef Ming Tsai shares an insider’s look at restaurant safety protocols, food allergy legislation and practical strategies physicians need to help patients with food allergies navigate the world with confidence.Find out more about food allergies. 

In this episode, we discuss the remarkable evolution of allergy and immunology through the lens of a career spanning six decades. Past AAAAI President Phil Lieberman, MD, FAAAAI, explores the pivotal scientific breakthroughs in the field starting with the discovery of IgE as he started in practice and taking us through target therapy has changed the lives of his patients. Dr. Lieberman offers us both historical perspective and guidance for physicians just starting in the field. Find out more about Dr. Lieberman.